MX2008009886A - Anticuerpos que enlazan par-2. - Google Patents
Anticuerpos que enlazan par-2.Info
- Publication number
- MX2008009886A MX2008009886A MX2008009886A MX2008009886A MX2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- par
- derivatives
- polypeptides
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77245606P | 2006-02-10 | 2006-02-10 | |
| PCT/US2007/003796 WO2007092640A2 (en) | 2006-02-10 | 2007-02-09 | Antibodies that bind par-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008009886A true MX2008009886A (es) | 2008-10-23 |
Family
ID=38345850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008009886A MX2008009886A (es) | 2006-02-10 | 2007-02-09 | Anticuerpos que enlazan par-2. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7888482B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1981913B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5255453B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007212195B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2638849C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2476892T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2008009886A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007092640A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| WO2009020748A2 (en) * | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
| WO2009046168A1 (en) | 2007-10-02 | 2009-04-09 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| WO2010017086A1 (en) * | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| WO2010132954A1 (en) * | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| MY162557A (en) | 2010-02-26 | 2017-06-15 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
| WO2012077105A2 (en) * | 2010-12-07 | 2012-06-14 | Bio-Marcare Technologies Ltd. | Biomarkers for detecting a cancerous state in a subject |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| HK1223096A1 (zh) | 2013-09-25 | 2017-07-21 | Vertex Pharmaceuticals Incorporated | 用作par-2信號通路抑制劑的咪唑並噠嗪 |
| WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| KR20220098056A (ko) * | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| KR20220069982A (ko) | 2019-09-26 | 2022-05-27 | 암젠 인크 | 항체 조성물의 생산 방법 |
| EP4045515A4 (en) | 2019-10-18 | 2023-10-18 | The Regents Of The University Of Michigan | BIOMATERIAL SENSOR SYSTEMS |
| WO2021247892A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| AU2021328375A1 (en) * | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| CN112229996A (zh) * | 2020-08-25 | 2021-01-15 | 深圳市第二人民医院(深圳市转化医学研究院) | 蛋白酶激活受体2作为宫颈癌转移检测标志物的应用 |
| US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| AU2022289365A1 (en) | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| JP2024537100A (ja) | 2021-10-05 | 2024-10-10 | アムジエン・インコーポレーテツド | Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量 |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| JP2026516670A (ja) | 2023-04-20 | 2026-05-26 | アムジエン・インコーポレーテツド | 相対的な不対グリカン含有量を決定する方法 |
| AU2024325342A1 (en) | 2023-08-14 | 2026-02-26 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2026090253A1 (en) | 2024-10-23 | 2026-04-30 | Amgen Inc. | Methods of determining glycan pairing content |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629174A (en) | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| US6297026B1 (en) | 1993-07-26 | 2001-10-02 | Cor Therapeutics Inc. | Nucleic acids encoding the C140 receptor |
| AU5895500A (en) * | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| AU2001231030A1 (en) | 2000-01-20 | 2001-07-31 | Amgen Inc | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
| US20070053911A1 (en) | 2003-03-11 | 2007-03-08 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| WO2010017086A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
-
2007
- 2007-02-08 US US11/704,529 patent/US7888482B2/en active Active
- 2007-02-09 WO PCT/US2007/003796 patent/WO2007092640A2/en not_active Ceased
- 2007-02-09 AU AU2007212195A patent/AU2007212195B2/en active Active
- 2007-02-09 MX MX2008009886A patent/MX2008009886A/es active IP Right Grant
- 2007-02-09 ES ES07763386.5T patent/ES2476892T3/es active Active
- 2007-02-09 EP EP07763386.5A patent/EP1981913B1/en active Active
- 2007-02-09 JP JP2008554427A patent/JP5255453B2/ja active Active
- 2007-02-09 CA CA2638849A patent/CA2638849C/en active Active
-
2011
- 2011-01-18 US US13/008,736 patent/US8287872B2/en active Active
-
2012
- 2012-09-27 US US13/629,373 patent/US20130189281A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8287872B2 (en) | 2012-10-16 |
| JP2009525758A (ja) | 2009-07-16 |
| WO2007092640A3 (en) | 2008-01-10 |
| US7888482B2 (en) | 2011-02-15 |
| US20070237759A1 (en) | 2007-10-11 |
| US20110165171A1 (en) | 2011-07-07 |
| ES2476892T3 (es) | 2014-07-15 |
| CA2638849C (en) | 2014-07-08 |
| EP1981913B1 (en) | 2014-06-25 |
| WO2007092640A2 (en) | 2007-08-16 |
| AU2007212195A1 (en) | 2007-08-16 |
| JP5255453B2 (ja) | 2013-08-07 |
| US20130189281A1 (en) | 2013-07-25 |
| EP1981913A2 (en) | 2008-10-22 |
| AU2007212195B2 (en) | 2012-02-02 |
| CA2638849A1 (en) | 2007-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007092640A3 (en) | Antibodies that bind par-2 | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| PH12012501006A1 (en) | Compositions and methods relating to anti-igf-1 receptor antibodies | |
| MX2009002571A (es) | Anticuerpos anti-activina a y usos de los mismos. | |
| WO2008136848A3 (en) | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease | |
| WO2013192596A3 (en) | Antigen binding proteins that bind ccr2 | |
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| MY162624A (en) | Antibodies directed to her-3 and uses thereof | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| MX353319B (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
| HK1204557A1 (en) | Antigen binding proteins that bind pd-l1 | |
| WO2004013180A3 (en) | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof | |
| MY163032A (en) | Human anti-il-23 antibodies, compositions, methods and uses | |
| WO2009139853A3 (en) | Human monoclonal antibodies against human chemokine receptor ccr7 | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2007131133A8 (en) | Methods and compositions relating to zpa polypeptides | |
| WO2007075914A3 (en) | Monoclonal antibodies against orthopoxviruses | |
| WO2006029176A3 (en) | Cancer-testis antigens | |
| WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
| WO2007011765A3 (en) | Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides | |
| UA98632C2 (ru) | Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний | |
| AU2016219676A1 (en) | Anti-activin A antibodies and uses thereof | |
| WO2007065124A3 (en) | Methods of identifying and treating individuals exhibiting complex karyotypes | |
| WO2006091326A8 (en) | Anti-prl-3 antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |